Ginkgo Bioworks Holdings Profit Margin

Ginkgo Bioworks Holdings (DNA) currently reports a profit margin of -249.84% as of March 2026. That compares with -198.84% in the prior-year period — down 25.6% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Ginkgo Bioworks Holdings's profit margin history and peer comparisons.

Ginkgo Bioworks Holdings's profit margin decreased from -198.84% to -249.84% — a 25.6% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ginkgo Bioworks Holdings's profit margin of -249.84% is lower than the Healthcare sector average of 15.29%. That is roughly 1733.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Ginkgo Bioworks Holdings's current -249.84% should be judged against Healthcare norms (sector average: 15.29%) and against DNA's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -249.84%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Ginkgo Bioworks Holdings, and consider following DNA for alerts when major investors trade the stock.